Another terrific result from the @RaceOncology team.
Amgen reported sales of KYPROLIS® (carfilzomib) for Q1 2024 of $US 376 mill (an increase of 5% yoy), so annualised at more than $US 1.5 bill !!!
This is a lot of revenue they surely would like to protect beyond 2027. Bring on the licencing deal !
https://www.biospace.com/article/releases/amgen-reports-first-quarter-2024-financial-results/
Another terrific result from the @RaceOncology team.Amgen...
-
- There are more pages in this discussion • 67 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.57 |
Change
0.000(0.00%) |
Mkt cap ! $270.9M | |||
| Open | High | Low | Value | Volume |
| $1.59 | $1.62 | $1.57 | $119.0K | 75.05K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 27451 | $1.57 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.59 | 546 | 2 |
View Market Depth
| Last trade - 12.21pm 16/08/2024 (20 minute delay) ? |
| RAC (ASX) Chart |